Page last updated: 2024-12-06

3-methylxanthine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-Methylxanthine is a naturally occurring methylxanthine compound found in various plants, including coffee beans. It exhibits stimulant properties, similar to caffeine, and is known to increase heart rate, promote wakefulness, and enhance cognitive function. Its synthesis involves methylation of xanthine at the 3-position. Research on 3-methylxanthine focuses on its potential therapeutic applications, particularly in treating conditions like asthma and cognitive decline. Notably, it has shown promise as a bronchodilator and is being explored for its neuroprotective effects. The compound's structure and pharmacological properties are of interest to scientists due to its potential for developing novel drugs.'

3-methyl-9H-xanthine : A 3-methylxanthine tautomer where the imidazole proton is located at the 9-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

3-methyl-7H-xanthine : A 3-methylxanthine tautomer where the imidazole proton is located at the 7-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID70639
CHEMBL ID619
CHEBI ID62207
CHEBI ID62208
SCHEMBL ID237146
SCHEMBL ID8663339
MeSH IDM0094568

Synonyms (99)

Synonym
BIDD:GT0266
3-methyl-2,3,6,7-tetrahydro-1h-purine-2,6-dione
DIVK1C_006833
3-methyl-7h-purine-2,6-dione
SPECTRUM_001898
SPECTRUM4_001571
SPECTRUM5_001544
3-methyl xanthine
BSPBIO_003403
OPREA1_288071
OPREA1_233226
nsc515466
xanthine, 3-methyl-
nsc-515466
1h-purine-2, 3,7-dihydro-3-methyl-
wln: t56 bm dn fnvmvj f1
3 mx
3-methyl-9h-purine-2,6-dione
3-methylxanthine ,
3-methyl-3,9-dihydro-purine-2,6-dione
1076-22-8
3-methylxanthine, 98%
NCGC00095330-01
3,7-dihydro-3-methyl-1h-purine-2,6-dione
einecs 214-058-1
1h-purine-2,6-dione, 3,7-dihydro-3-methyl-
nsc 515466
ccris 5817
KBIO2_004990
KBIOSS_002428
KBIO2_002422
KBIO3_002623
KBIO1_001777
KBIOGR_002122
KBIO2_007558
SPECTRUM3_001652
SPBIO_000423
SPECPLUS_000737
SPECTRUM2_000502
SPECTRUM1504182
NCGC00178088-01
M2073
CHEMBL619 ,
chebi:62207 ,
2,6-dihydroxy-3-methylpurine
3-methyl-3,9-dihydro-purine-2,6-dione(3-methyl xanthine)
bdbm50001515
1-methylxanthine (1-mx)
3-methyl-3,7-dihydro-purine-2,6-dione
AKOS002272340
3-methyl-7h-purine-2,6-dione;3-methylxanthine
A801730
AKOS004120009
NCGC00095330-02
3-methyl-3,9-dihydro-1h-purine-2,6-dione
STK776266
n(1)-demethyltheophylline
3-methyl-7h-xanthine
3-methyl-3,7-dihydro-1h-purine-2,6-dione
2-oxo-3-methylhypoxanthine
3-methyl-3,7(9)-dihydro-purine-2,6-dione
CHEBI:62208
3-methyl-9h-xanthine
3-methyl-3,9-dihydro-2h,6h-purine-2,6-dione
3,9-dihydro-3-methyl-1h-purine-2,6-dione
3-methyl-1h-purine-2,6(3h,9h)-dione
BBL012772
AKOS006221835
CCG-39565
ws6x982oec ,
unii-ws6x982oec
3-methyl-1h-purine-2,6(3h,7h)-dione
FT-0616197
AM20080030
S6186
SCHEMBL237146
theophylline impurity b [ep impurity]
pentoxifylline impurity b [ep impurity]
theophylline monohydrate impurity b [ep impurity]
3-methyl-3,7-dihydropurine-2,6-dione
3-methyl-xanthine
3-methyl-3,9-dihydro-1h-purine-2,6-dione #
SCHEMBL8663339
DS-1280
CS-W020049
W-108741
mfcd00005580
DTXSID90148107
Z1741977122
GEO-01981
3-methyl-3,7-dihydro-1h-purine-2,6-dione (3-methylxanthine)
J-505016
HY-50723
SY031706
BCP18161
Q27888118
linagliptin intermediates
EN300-212022
PD001242

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The half-life of elimination from plasma was more than four times longer in Cyp1a2(-/-) than Cyp1(+/+) mice and more than 10 times different after TCDD pretreatment."( Theophylline pharmacokinetics: comparison of Cyp1a1(-/-) and Cyp1a2(-/-) knockout mice, humanized hCYP1A1_1A2 knock-in mice lacking either the mouse Cyp1a1 or Cyp1a2 gene, and Cyp1(+/+) wild-type mice.
Curran, CP; Dalton, TP; Derkenne, S; Dragin, N; Nebert, DW; Shertzer, HG, 2005
)
0.33

Dosage Studied

ExcerptRelevanceReference
" Dosage of each quinolone was 200 mg twice daily for four days, starting three days prior to the theophylline infusion."( Drug-drug interactions affecting fluoroquinolones.
Guelen, PJ; Janssen, TJ; Vree, TB; Wijnands, GJ, 1989
)
0.28
" The addition of enoxacin (400 mg, twice daily) to a theophylline dosing regimen (150 mg, twice daily) resulted in an immediate fall in plasma theophylline metabolite concentrations."( The theophylline-enoxacin interaction: II. Changes in the disposition of theophylline and its metabolites during intermittent administration of enoxacin.
Koup, JR; Rogge, MC; Sedman, AJ; Solomon, WR; Wagner, JG; Welling, PG, 1989
)
0.28
", twice daily for 11 days in a sustained release dosage form."( Enoxacin--a potent inhibitor of theophylline metabolism.
Beckmann, J; Elsässer, W; Gundert-Remy, U; Hertrampf, R, 1987
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
3-methylxanthineA monomethylxanthine having the methyl group located at the 3-position. It is a metabolite of caffeine.
3-methylxanthineA monomethylxanthine having the methyl group located at the 3-position. It is a metabolite of caffeine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
theophylline degradation315
theobromine biosynthesis II (via xanthine)06
caffeine degradation I (main, plants)04

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency15.81140.140911.194039.8107AID2451
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine receptor A1Rattus norvegicus (Norway rat)Ki35.00000.00011.20929.9700AID32491
Adenosine receptor A2aHomo sapiens (human)Ki240.00000.00001.06099.7920AID30797
Adenosine receptor A2bHomo sapiens (human)Ki240.00000.00021.635210.0000AID30797
Adenosine receptor A2bRattus norvegicus (Norway rat)Ki240.00000.00061.353610.0000AID30797
Adenosine receptor A2aRattus norvegicus (Norway rat)Ki240.00000.00021.494010.0000AID30797
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine receptor A2aHomo sapiens (human)EC50 (µMol)100.00000.00030.708110.0000AID74022
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (61)

Processvia Protein(s)Taxonomy
synaptic transmission, dopaminergicAdenosine receptor A2aHomo sapiens (human)
response to amphetamineAdenosine receptor A2aHomo sapiens (human)
regulation of DNA-templated transcriptionAdenosine receptor A2aHomo sapiens (human)
phagocytosisAdenosine receptor A2aHomo sapiens (human)
apoptotic processAdenosine receptor A2aHomo sapiens (human)
inflammatory responseAdenosine receptor A2aHomo sapiens (human)
cellular defense responseAdenosine receptor A2aHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
cell-cell signalingAdenosine receptor A2aHomo sapiens (human)
synaptic transmission, cholinergicAdenosine receptor A2aHomo sapiens (human)
central nervous system developmentAdenosine receptor A2aHomo sapiens (human)
blood coagulationAdenosine receptor A2aHomo sapiens (human)
sensory perceptionAdenosine receptor A2aHomo sapiens (human)
locomotory behaviorAdenosine receptor A2aHomo sapiens (human)
blood circulationAdenosine receptor A2aHomo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A2aHomo sapiens (human)
response to xenobiotic stimulusAdenosine receptor A2aHomo sapiens (human)
response to inorganic substanceAdenosine receptor A2aHomo sapiens (human)
positive regulation of glutamate secretionAdenosine receptor A2aHomo sapiens (human)
positive regulation of acetylcholine secretion, neurotransmissionAdenosine receptor A2aHomo sapiens (human)
regulation of norepinephrine secretionAdenosine receptor A2aHomo sapiens (human)
response to purine-containing compoundAdenosine receptor A2aHomo sapiens (human)
response to caffeineAdenosine receptor A2aHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicAdenosine receptor A2aHomo sapiens (human)
synaptic transmission, glutamatergicAdenosine receptor A2aHomo sapiens (human)
positive regulation of urine volumeAdenosine receptor A2aHomo sapiens (human)
vasodilationAdenosine receptor A2aHomo sapiens (human)
eating behaviorAdenosine receptor A2aHomo sapiens (human)
negative regulation of vascular permeabilityAdenosine receptor A2aHomo sapiens (human)
negative regulation of neuron apoptotic processAdenosine receptor A2aHomo sapiens (human)
positive regulation of circadian sleep/wake cycle, sleepAdenosine receptor A2aHomo sapiens (human)
negative regulation of alpha-beta T cell activationAdenosine receptor A2aHomo sapiens (human)
astrocyte activationAdenosine receptor A2aHomo sapiens (human)
neuron projection morphogenesisAdenosine receptor A2aHomo sapiens (human)
positive regulation of protein secretionAdenosine receptor A2aHomo sapiens (human)
negative regulation of inflammatory responseAdenosine receptor A2aHomo sapiens (human)
regulation of mitochondrial membrane potentialAdenosine receptor A2aHomo sapiens (human)
membrane depolarizationAdenosine receptor A2aHomo sapiens (human)
regulation of calcium ion transportAdenosine receptor A2aHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicAdenosine receptor A2aHomo sapiens (human)
excitatory postsynaptic potentialAdenosine receptor A2aHomo sapiens (human)
inhibitory postsynaptic potentialAdenosine receptor A2aHomo sapiens (human)
prepulse inhibitionAdenosine receptor A2aHomo sapiens (human)
apoptotic signaling pathwayAdenosine receptor A2aHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A2aHomo sapiens (human)
positive regulation of long-term synaptic potentiationAdenosine receptor A2aHomo sapiens (human)
positive regulation of apoptotic signaling pathwayAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A2bHomo sapiens (human)
positive regulation of chronic inflammatory response to non-antigenic stimulusAdenosine receptor A2bHomo sapiens (human)
G protein-coupled receptor signaling pathwayAdenosine receptor A2bHomo sapiens (human)
activation of adenylate cyclase activityAdenosine receptor A2bHomo sapiens (human)
positive regulation of vascular endothelial growth factor productionAdenosine receptor A2bHomo sapiens (human)
positive regulation of cGMP-mediated signalingAdenosine receptor A2bHomo sapiens (human)
cGMP-mediated signalingAdenosine receptor A2bHomo sapiens (human)
positive regulation of chemokine productionAdenosine receptor A2bHomo sapiens (human)
positive regulation of interleukin-6 productionAdenosine receptor A2bHomo sapiens (human)
mast cell degranulationAdenosine receptor A2bHomo sapiens (human)
positive regulation of mast cell degranulationAdenosine receptor A2bHomo sapiens (human)
relaxation of vascular associated smooth muscleAdenosine receptor A2bHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A2bHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2bHomo sapiens (human)
vasodilationAdenosine receptor A2bHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
G protein-coupled adenosine receptor activityAdenosine receptor A2aHomo sapiens (human)
protein bindingAdenosine receptor A2aHomo sapiens (human)
calmodulin bindingAdenosine receptor A2aHomo sapiens (human)
lipid bindingAdenosine receptor A2aHomo sapiens (human)
enzyme bindingAdenosine receptor A2aHomo sapiens (human)
type 5 metabotropic glutamate receptor bindingAdenosine receptor A2aHomo sapiens (human)
identical protein bindingAdenosine receptor A2aHomo sapiens (human)
protein-containing complex bindingAdenosine receptor A2aHomo sapiens (human)
alpha-actinin bindingAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2bHomo sapiens (human)
protein bindingAdenosine receptor A2bHomo sapiens (human)
G protein-coupled receptor activityAdenosine receptor A2bHomo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2aRattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Processvia Protein(s)Taxonomy
plasma membraneAdenosine receptor A2aHomo sapiens (human)
intermediate filamentAdenosine receptor A2aHomo sapiens (human)
plasma membraneAdenosine receptor A2aHomo sapiens (human)
membraneAdenosine receptor A2aHomo sapiens (human)
dendriteAdenosine receptor A2aHomo sapiens (human)
axolemmaAdenosine receptor A2aHomo sapiens (human)
asymmetric synapseAdenosine receptor A2aHomo sapiens (human)
presynaptic membraneAdenosine receptor A2aHomo sapiens (human)
neuronal cell bodyAdenosine receptor A2aHomo sapiens (human)
postsynaptic membraneAdenosine receptor A2aHomo sapiens (human)
presynaptic active zoneAdenosine receptor A2aHomo sapiens (human)
glutamatergic synapseAdenosine receptor A2aHomo sapiens (human)
plasma membraneAdenosine receptor A2bHomo sapiens (human)
Schaffer collateral - CA1 synapseAdenosine receptor A2bHomo sapiens (human)
presynapseAdenosine receptor A2bHomo sapiens (human)
glutamatergic synapseAdenosine receptor A2bHomo sapiens (human)
plasma membraneAdenosine receptor A2bHomo sapiens (human)
Golgi membraneAdenosine receptor A2aRattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID30807Binding affinity against Adenosine A2 receptor in rat striatal membranes using [3H]5'-(N-ethylcarboxamido)-adenosine (NECA) as the ligand1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
Synthesis of paraxanthine analogs (1,7-disubstituted xanthines) and other xanthines unsubstituted at the 3-position: structure-activity relationships at adenosine receptors.
AID32156Affinity against adenosine A2 receptor in brain membranes by displacement of [3H]CPX1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Effects of alkyl substitutions of xanthine skeleton on bronchodilation.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID219846Inhibition of c-AMP phosphodiesterase activity in guinea pig tracheal muscle1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Effects of alkyl substitutions of xanthine skeleton on bronchodilation.
AID32667Binding affinity at Adenosine A1 receptor in rat brain cortical membrane using [3H]- N6-R-phenylisopropyladenosine (R-PIA) at 100 uM1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
Synthesis of paraxanthine analogs (1,7-disubstituted xanthines) and other xanthines unsubstituted at the 3-position: structure-activity relationships at adenosine receptors.
AID32491Inhibition of 1 nM [3H]- N6-(phenylisopropyl) adenosine binding to Adenosine A1 receptor in rat cerebral cortical membranes1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Effects of 8-phenyl and 8-cycloalkyl substituents on the activity of mono-, di-, and trisubstituted alkylxanthines with substitution at the 1-, 3-, and 7-positions.
AID75917Positive chronotropic effect on isolated guinea pig right atrium (heart stimulation).1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Effects of alkyl substitutions of xanthine skeleton on bronchodilation.
AID227877Ratio of stimulatory activity in right atrium to relaxant activity in tracheal muscle1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Effects of alkyl substitutions of xanthine skeleton on bronchodilation.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID74022Relaxant activity on the spontaneous tone of isolated guinea pig tracheal ring chains.1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Effects of alkyl substitutions of xanthine skeleton on bronchodilation.
AID55471Binding affinity to DNA intercalator Acridine orange.2001Journal of medicinal chemistry, Dec-20, Volume: 44, Issue:26
Structural basis for the binding affinity of xanthines with the DNA intercalator acridine orange.
AID30797Inhibition of the stimulation by 5'-(N-ethylcarbamoyl) adenosine of adenyl cyclase via adenosine A2 receptor in human platelet membranes.1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Effects of 8-phenyl and 8-cycloalkyl substituents on the activity of mono-, di-, and trisubstituted alkylxanthines with substitution at the 1-, 3-, and 7-positions.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (57)

TimeframeStudies, This Drug (%)All Drugs %
pre-199022 (38.60)18.7374
1990's14 (24.56)18.2507
2000's7 (12.28)29.6817
2010's11 (19.30)24.3611
2020's3 (5.26)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 40.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index40.53 (24.57)
Research Supply Index4.19 (2.92)
Research Growth Index4.58 (4.65)
Search Engine Demand Index56.48 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (40.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (6.56%)5.53%
Reviews1 (1.64%)6.00%
Case Studies2 (3.28%)4.05%
Observational0 (0.00%)0.25%
Other54 (88.52%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]